Use of adipose-derived stem cells in lymphatic tissue engineering and regeneration

The potential to differentiate into different cell lines, added to the easy and cost-effective method of extraction, makes adipose-derived stem cells (ADSCs) an object of interest in lymphedema treatment. Our study’s goal was to conduct a comprehensive systematic review of the use of ADSCs in lymphatic tissue engineering and regeneration. On July 23, 2019, using PubMed/MEDLINE, Cochrane Clinical Answers, Cochrane Central Register of Controlled Trials, and Embase databases, we conducted a systematic review of published literature on the use of ADSCs in lymphatic tissue engineering and regeneration. There were no language or time frame limitations, and the following search strategy was applied: ((Adipose stem cell) OR Adipose-derived stem cell)) AND ((Lymphedema) OR Breast Cancer Lymphedema). Only original research manuscripts were included. Fourteen studies fulfilled the inclusion criteria. Eleven studies were experimental (in vitro or in vivo in animals), and only three were clinical. Publications on the topic demonstrated that ADSCs promote lymphangiogenesis, and its effect could be enhanced by modulation of vascular endothelial growth factor-C, interleukin-7, prospero homeobox protein 1, and transforming growth factor-β1. Pilot clinical studies included 11 patients with breast cancer-related lymphedema, and no significant side effects were present at 12-month follow-up. Literature on the use of ADSCs in lymphatic tissue engineering and regeneration demonstrated promising data. Clinical evidence is still in its infancy, but the scientific community agrees that ADSCs can be useful in regenerative lymphangiogenesis. Data collected in this review indicate that unprecedented advances in lymphedema treatment can be anticipated in the upcoming years.

Keywords

Adipose-derived mesenchymal stem cells - Regenerative medicine - Lymphatic vessels - Lymphedema

Publication History

Received: 07 February 2021

Accepted: 16 June 2021

Article published online:
19 March 2022

• REFERENCES

• 1 Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 2009; 59: 8-24
• 2 Basta MN, Wu LC, Kanchwala SK. et al. Reliable prediction of postmastectomy lymphedema: the Risk Assessment Tool Evaluating Lymphedema. Am J Surg 2017; 213: 1125-33
• 3 DiSipio T, Rye S, Newman B. et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013; 14: 500-15
• 4 McDuff SGR, Mina AI, Brunelle CL. et al. Timing of lymphedema after treatment for breast cancer: when are patients most at risk?. Int J Radiat Oncol Biol Phys 2019; 103: 62-70
• 5 Kayiran O, De La Cruz C, Tane K. et al. Lymphedema: from diagnosis to treatment. Turk J Surg 2017; 33: 51-7
• 6 Dayan JH, Ly CL, Kataru RP. et al. Lymphedema: pathogenesis and novel therapies. Annu Rev Med 2018; 69: 263-76
• 7 Breastcancer.org. Surgery for lymphedema [Internet]. Ardmore, PA: Breastcancer.org; c2021 [cited 2021 Apr 28]. Available from: https://www.breastcancer.org/treatment/lymphedema/treatments/surgery
• 8 Ceccarelli S, Pontecorvi P, Anastasiadou E. et al. Immunomodulatory effect of adipose-derived stem cells: the cutting edge of clinical application. Front Cell Dev Biol 2020; 8: 236
• 9 Gir P, Oni G, Brown SA. et al. Human adipose stem cells: current clinical applications. Plast Reconstr Surg 2012; 129: 1277-90
• 10 Toyserkani NM, Christensen ML, Sheikh SP. et al. Stem cells show promising results for lymphoedema treatment: a literature review. J Plast Surg Hand Surg 2015; 49: 65-71
• 11 Toyserkani NM, Jorgensen MG, Tabatabaeifar S. et al. Concise review: a safety assessment of adipose-derived cell therapy in clinical trials. A systematic review of reported adverse events. Stem Cells Transl Med 2017; 6: 1786-94
• 12 Toyserkani NM, Jensen CH, Sheikh SP. et al. Cell-assisted lipotransfer using autologous adipose-derived stromal cells for alleviation of breast cancer-related lymphedema. Stem Cells Transl Med 2016; 5: 857-9
• 13 Toyserkani NM, Jensen CH, Andersen DC. et al. Treatment of breast cancer-related lymphedema with adipose-derived regenerative cells and fat grafts: a feasibility and safety study. Stem Cells Transl Med 2017; 6: 1666-72
• 14 Toyserkani NM, Jensen CH, Tabatabaeifar S. et al. Adipose-derived regenerative cells and fat grafting for treating breast cancer-related lymphedema: lymphoscintigraphic evaluation with 1 year of follow-up. J Plast Reconstr Aesthet Surg 2019; 72: 71-7
• 15 Hwang JH, Kim IG, Lee JY. et al. Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel. Biomaterials 2011; 32: 4415-23
• 16 Yan A, Avraham T, Zampell JC. et al. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition. Future Oncol 2011; 7: 1457-73
• 17 Strassburg S, Torio-Padron N, Finkenzeller G. et al. Adiposederived stem cells support lymphangiogenic parameters in vitro. Cell Biochem 2016; 117: 2620-9
• 18 Deng J, Dai T, Sun Y. et al. Overexpression of Prox1 induces the differentiation of human adipose-derived stem cells into lymphatic endothelial-like cells in vitro. Cell Reprogram 2017; 19: 54-63
• 19 Sun Y, Lu B, Deng J. et al. IL-7 enhances the differentiation of adipose-derived stem cells toward lymphatic endothelial cells through AKT signaling. Cell Biol Int 2019; 43: 394-401
• 20 Takeda K, Sowa Y, Nishino K. et al. Adipose-derived stem cells promote proliferation, migration, and tube formation of lymphatic endothelial cells in vitro by secreting lymphangiogenic factors. Ann Plast Surg 2015; 74: 728-36
• 21 Saijo H, Suzuki K, Yoshimoto H. et al. Paracrine effects of adipose-derived stem cells promote lymphangiogenesis in irradiated lymphatic endothelial cells. Plast Reconstr Surg 2019; 143: 1189e-1200e
• 22 Shimizu Y, Shibata R, Shintani S. et al. Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells. J Am Heart Assoc 2012; 1: e000877
• 23 Yoshida S, Hamuy R, Hamada Y. et al. Adipose-derived stem cell transplantation for therapeutic lymphangiogenesis in a mouse secondary lymphedema model. Regen Med 2015; 10: 549-62
• 24 Hayashida K, Yoshida S, Yoshimoto H. et al. Adipose-derived stem cells and vascularized lymph node transfers successfully treat mouse hindlimb secondary lymphedema by early reconnection of the lymphatic system and lymphangiogenesis. Plast Reconstr Surg 2017; 139: 639-51
• 25 Ackermann M, Wettstein R, Senaldi C. et al. Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model. Microvasc Res 2015; 102: 78-85
• 26 Forte AJ, Boczar D, Huayllani MT. et al. Use of autologous blood components in lymphedema treatment: a systematic review. Cureus 2019; 11: e5638
• 27 Forte AJ, Boczar D, Huayllani MT. et al. Topical approach to delivering targeted therapies in lymphedema treatment: a systematic review. Cureus 2019; 11: e6269
• 28 Forte AJ, Huayllani MT, Boczar D. et al. Bioimpedance spectroscopy for assessment of breast cancer-related lymphedema: a systematic review. Plast Surg Nurs 2020; 40: 86-90
• 29 Joseph WJ, Aschen S, Ghanta S. et al. Sterile inflammation after lymph node transfer improves lymphatic function and regeneration. Plast Reconstr Surg 2014; 134: 60-8
• 30 Kondo K, Kaneko T, Baba M. et al. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30: 633-7
• 31 Wu SH, Shirado T, Mashiko T. et al. Therapeutic effects of human adipose-derived products on impaired wound healing in irradiated tissue. Plast Reconstr Surg 2018; 142: 383-91
• 32 Forte AJ, Boczar D, Huayllani MT. et al. Targeted therapies in surgical treatment of lymphedema: a systematic review. Cureus 2019; 11: e5397
• 33 Zampell JC, Elhadad S, Avraham T. et al. Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury. Am J Physiol Cell Physiol 2012; 302: C709-19
• 34 Avraham T, Zampell JC, Yan A. et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J 2013; 27: 1114-26